Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.52 |
| ▸ | PNMT | P11086 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.44 |
| ▸ | HTR5A | P47898 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887634 | 1.00 | CD44 (0.52) | CD44PNMTMAOBALOX15HSD17B10 | |
| Hydrochloric Acid SCHEMBL7002945 | 0.98 | CD44 (0.50) | CD44PNMTMAOBALOX15HSD17B10 | |
| SCHEMBL8144398 | 0.87 | CD44 (0.46) | CD44PNMTMAOBALOX15HSD17B10 | |
| SCHEMBL18320611 | 0.85 | PNMT (0.47) | CD44PNMTMAOBALOX15HSD17B10 | |
| SCHEMBL5739939 | 0.80 | HTR2C (0.62) | CD44PNMTMAOBALOX15HSD17B10 | |
| SCHEMBL11852161 | 0.80 | PNMT (0.75) | CD44PNMTMAOBALOX15HSD17B10 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL28542017 | 0.79 | PNMT (0.73) | CD44PNMTMAOBALOX15HSD17B10 | |
| SCHEMBL29411963 | 0.79 | ALOX15 (0.50) | CD44PNMTMAOBALOX15HSD17B10 | |
| SCHEMBL124019 | 0.79 | ALOX15 (0.50) | CD44PNMTMAOBALOX15HSD17B10 | |
| SCHEMBL3757557 | 0.78 | ALOX15 (0.41) | CD44PNMTMAOBALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025105341-A1 | METAL PATTERNING MATERIAL, PENTAFLUOROSULFANYL COMPOUND, METAL PATTERNING THIN FILM, ORGANIC ELECTROLUMINESCENT ELEMENT, ELECTRONIC APPARATUS, AND METAL PATTERN FORMING METHOD | 東ソー株式会社 | 2025-05-22 | — | — | WO | claimed |
| WO-2025028487-A1 | MATERIAL FOR METAL PATTERNING, HETEROCYCLIC COMPOUND, THIN FILM FOR METAL PATTERNING, ORGANIC ELECTROLUMINESCENT ELEMENT, ELECTRONIC DEVICE, AND METHOD FOR FORMING METAL PATTERN | 東ソー株式会社 | 2025-02-06 | — | — | WO | claimed |
| WO-2024248132-A1 | METAL PATTERNING MATERIAL, HETEROCYCLIC COMPOUND, THIN FILM FOR METAL PATTERNING, ORGANIC ELECTROLUMINESCENCE ELEMENT, ELECTRONIC APPARATUS, AND METAL PATTERN FORMATION METHOD | 東ソー株式会社 | 2024-12-05 | — | — | WO | claimed |
| WO-2022057142-A1 | STEROID SYNTHETASE INHIBITORS AND THERAPEUTIC USE THEREOF | 广州中医药大学(广州中医药研究院) | 2022-03-24 | — | — | WO | claimed |
| US-20100143322-A1 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT PATENT & LICENCE TRADING LTD., C/O THE B-NET (GB) | 2010-06-10 | — | — | US | claimed |
| EP-1917006-A2 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT Patent & Licence Trading Ltd. (GB) | 2008-05-07 | — | — | EP | claimed |
| WO-2006136454-A2 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT PATENT & LICENCE TRADING LTD. (GB) | 2006-12-28 | — | — | WO | claimed |
| EP-1140786-B9 | REDUCTIVE ALKYLATION OF SECONDARY AMINES WITH HYDROSILANE | BRISTOL MYERS SQUIBB CO (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1140786-B1 | REDUCTIVE ALKYLATION OF SECONDARY AMINES WITH HYDROSILANE | BRISTOL MYERS SQUIBB CO (US) | 2005-11-30 | — | — | EP | claimed |
| US-6949642-B2 | Production of tertiary amines by reductive amination | BRISTOL-MYERS SQUIBB CO. (US) | 2005-09-27 | — | — | US | claimed |
| EP-1027042-A4 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2004-08-18 | — | — | EP | claimed |
| US-20030130257-A1 | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-10 | — | — | US | claimed |
| US-20020169313-A1 | Production of tertiary amines by reductive amination | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-14 | — | — | US | claimed |
| EP-1027042-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-16 | — | — | EP | claimed |
| US-5985869-A | USEFUL AS VASODILATORS, HYPOTENSIVE AGENTS, WATER DIURETICS, PLATELET AGGLUTINATION INHIBITORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1999-11-16 | — | — | US | claimed |
| WO-1999018951-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-04-22 | — | — | WO | claimed |
| US-5559230-A | VASOPRESSIN ANTAGONISTS, QUINOLINES, BENZAZEPINES, VASODILATION, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-24 | — | — | US | claimed |
| EP-0450097-B1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 1996-04-24 | — | — | EP | claimed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | claimed |
| WO-2025105341-A1 | METAL PATTERNING MATERIAL, PENTAFLUOROSULFANYL COMPOUND, METAL PATTERNING THIN FILM, ORGANIC ELECTROLUMINESCENT ELEMENT, ELECTRONIC APPARATUS, AND METAL PATTERN FORMING METHOD | 東ソー株式会社 | 2025-05-22 | — | — | WO | disclosed |
| US-20250154114-A1 | MATERIAL FOR METAL PATTERNING, HETEROCYCLIC COMPOUND, THIN FILM FOR METAL PATTERNING, ORGANIC ELECTROLUMINESCENT DEVICE, ELECTRONIC DEVICE, AND METHOD FOR FORMING METAL PATTERN | TOSOH CORPORATION (JP) | 2025-05-15 | — | — | US | disclosed |
| CN-116178337-B | Benzodiazepine compounds and their use as Rho kinase inhibitors | 成都奥睿药业有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025028487-A1 | MATERIAL FOR METAL PATTERNING, HETEROCYCLIC COMPOUND, THIN FILM FOR METAL PATTERNING, ORGANIC ELECTROLUMINESCENT ELEMENT, ELECTRONIC DEVICE, AND METHOD FOR FORMING METAL PATTERN | 東ソー株式会社 | 2025-02-06 | — | — | WO | disclosed |
| CN-119285628-A | Compounds for the treatment and prophylaxis of respiratory syncytial virus infection diseases | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2024248132-A1 | METAL PATTERNING MATERIAL, HETEROCYCLIC COMPOUND, THIN FILM FOR METAL PATTERNING, ORGANIC ELECTROLUMINESCENCE ELEMENT, ELECTRONIC APPARATUS, AND METAL PATTERN FORMATION METHOD | 東ソー株式会社 | 2024-12-05 | — | — | WO | disclosed |
| CN-118696625-A | Material for metal patterning, heterocyclic compound, thin film for metal patterning, organic electroluminescent element, electronic device, and method for forming metal pattern | 东曹株式会社 | 2024-09-24 | — | — | CN | disclosed |
| EP-4067347-B1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240018129-A1 | COMPOUNDS AS PU. 1 INHIBITORS | S-Infinity Pharmaceuticals (CN) | 2024-01-18 | — | — | US | disclosed |
| EP-3782995-B1 | SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023153482-A1 | MATERIAL FOR METAL PATTERNING, HETEROCYCLIC COMPOUND, THIN FILM FOR METAL PATTERNING, ORGANIC ELECTROLUMINESCENT DEVICE, ELECTRONIC DEVICE, AND METHOD FOR FORMING METAL PATTERN | 東ソー株式会社 | 2023-08-17 | — | — | WO | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-3250035-B1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS INC (TW) | 2023-01-25 | — | — | EP | disclosed |
| US-11535607-B2 | Isoindolines as HDAC inhibitors | VALO HEALTH, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| EP-4067347-A1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 FOR THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-115028617-A | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer | 基因泰克公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-109476641-B | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer | 基因泰克公司 | 2022-07-05 | — | — | CN | disclosed |
| EP-3097078-B1 | PYRIDINES AND PYRIMIDINES AND USE THEREOF | PURDUE PHARMA LP (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2022057142-A1 | STEROID SYNTHETASE INHIBITORS AND THERAPEUTIC USE THEREOF | 广州中医药大学(广州中医药研究院) | 2022-03-24 | — | — | WO | disclosed |
| EP-3464270-B1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 AND THEIR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3464270-B1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 AND THEIR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220002278-A9 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | SUZHOU INSTITUTE OF MATERIA MEDICA (CN) | 2022-01-06 | — | — | US | disclosed |
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO EARLY DISCOVERY, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-11001698-B2 | Stabilizer composition | BASF SE | 2021-05-11 | — | — | US | disclosed |
| US-20210101891-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-04-08 | — | — | US | disclosed |
| EP-3784654-A1 | ISOINDOLINES AS HDAC INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3782995-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-02-24 | — | — | EP | disclosed |
| CN-112292370-A | Isoindolines as HDAC inhibitors | 瓦洛早期发现股份有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | AbbVie Deutschland GmbH & Co. KG (DE) | 2021-01-21 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-10870635-B2 | Compounds and their use as BACE1 inhibitors | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2020-12-22 | — | — | US | disclosed |
| CN-107613771-B | Compounds and their use as beta-secretase 1 inhibitors | 新源生物科技股份有限公司 | 2020-12-15 | — | — | CN | disclosed |
| US-10836688-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10786580-B2 | Cholecystokinin 2 receptor targeted NIR imaging and use thereof | On Target Laboratories, LLC (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200283439-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-09-10 | — | — | US | disclosed |
| US-10696655-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696655-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10683256-B2 | Process for preparing substituted biphenyls | BASF SE (DE) | 2020-06-16 | — | — | US | disclosed |
| US-20200148610-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | ABBVIE INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200048394-A1 | HARDENABLE POLYMER COMPOSITION | BASF SE (DE) | 2020-02-13 | — | — | US | disclosed |
| US-20200048431-A1 | STABILIZER COMPOSITION | BASF SE (DE) | 2020-02-13 | — | — | US | disclosed |
| WO-2019204550-A1 | ISOINDOLINES AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019201291-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | 中国科学院上海药物研究所 | 2019-10-24 | — | — | WO | disclosed |
| EP-3115361-B1 | HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2019-10-23 | — | — | EP | disclosed |
| CN-110177565-A | 2 receptor target near infrared imaging of cholecystokinin and application thereof | 目标实验室有限责任公司 | 2019-08-27 | — | — | CN | disclosed |
| EP-3509617-A1 | CHOLECYSTOKININ 2 RECEPTOR TARGETED NIR IMAGING AND USE THEREOF | On Target Laboratories, LLC (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190210954-A1 | Process for Preparing Substituted Biphenyls | LIANHE CHEMICAL TECHNOLOGY CO., LTD (CN) | 2019-07-11 | — | — | US | disclosed |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| EP-2958919-B1 | DIHYDROPTERIDINONES I | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| EP-3464270-A2 | HETEROCYCLIC INHIBITORS OF CBP/EP300 AND THEIR USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2019-04-10 | — | — | EP | disclosed |
| CN-109476641-A | Heterocyclic inhibitors of CBP/EP300 and their use in the treatment of cancer | 基因泰克公司 | 2019-03-15 | — | — | CN | disclosed |
| US-20190071443-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-03-07 | — | — | US | disclosed |
| US-10174011-B2 | Heterocyclic compounds, process for preparation of the same and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-01-08 | — | — | US | disclosed |
| US-10118926-B2 | Tricyclic quinoline and quinoxaline derivatives | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-11-06 | — | — | US | disclosed |
| CN-108358893-A | A kind of method of one pot process tetrahydro benzo-[1,4]-diazepan derivatives | 安徽唯诗杨信息科技有限公司 | 2018-08-03 | — | — | CN | disclosed |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2018-07-19 | — | — | US | disclosed |
| EP-2882749-B1 | 4-METHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALENES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-04 | — | — | EP | disclosed |
| US-20180071408-A1 | CHOLECYSTOKININ 2 RECEPTOR TARGETED NIR IMAGING AND USE THEREOF | On Target Laboratories, Inc. | 2018-03-15 | — | — | US | disclosed |
| WO-2018049129-A1 | CHOLECYSTOKININ 2 RECEPTOR TARGETED NIR IMAGING AND USE THEREOF | On Target Laboratories, LLC (US) | 2018-03-15 | — | — | WO | disclosed |
| US-9849138-B2 | 1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849138-B2 | 1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-12-26 | — | — | US | disclosed |
| EP-3250035-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | Allgenesis Biotherapeutics Inc. (TW) | 2017-12-06 | — | — | EP | disclosed |
| WO-2017205536-A2 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017205536-A2 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-9789082-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170217850-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | ABBVIE INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217850-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | ABBVIE INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170158680-A1 | HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-06-08 | — | — | US | disclosed |
| US-20170014381-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2017-01-19 | — | — | US | disclosed |
| US-20170008882-A1 | PYRIDINES AND PYRIMIDINES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-01-12 | — | — | US | disclosed |
| US-20170008882-A1 | PYRIDINES AND PYRIMIDINES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-01-12 | — | — | US | disclosed |
| EP-3115361-A1 | HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2017-01-11 | — | — | EP | disclosed |
| US-20160346186-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-12-01 | — | — | US | disclosed |
| WO-2016172255-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2016-10-27 | — | — | WO | disclosed |
| EP-2766370-B1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2016-08-03 | — | — | EP | disclosed |
| US-9309200-B2 | Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-04-12 | — | — | US | disclosed |
| US-20160095866-A1 | 1,4-Benzodiazepone-2,5-Diones And Related Compounds With Therapeutic Properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-04-07 | — | — | US | disclosed |
| EP-2742039-B1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2015-09-16 | — | — | EP | disclosed |
| WO-2015131856-A1 | HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF | 中国科学院上海药物研究所 | 2015-09-11 | — | — | WO | disclosed |
| US-9126978-B2 | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126978-B2 | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-08 | — | — | US | disclosed |
| US-9096546-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096546-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096546-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| WO-2015112801-A1 | PYRIDINES AND PYRIMIDINES AND USE THEREOF | PURDUE PHARMA L.P. (US) | 2015-07-30 | — | — | WO | disclosed |
| EP-2895485-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-9085584-B2 | Substituted pyrido[3,2-E][1,2,4]-triazolo[4,3-A]pyrazines for the treatment of central nervous system disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-9085584-B2 | Substituted pyrido[3,2-E][1,2,4]-triazolo[4,3-A]pyrazines for the treatment of central nervous system disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-9006226-B2 | Dihydropteridinones I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006226-B2 | Dihydropteridinones I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-8889732-B2 | Fused heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-8889732-B2 | Fused heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-8871756-B2 | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease | HOFFMANN-LA ROCHE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8815845-B2 | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815845-B2 | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2766370-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-8778957-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778957-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2742039-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-20140080816-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-20 | — | — | US | disclosed |
| WO-2014041131-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-03-20 | — | — | WO | disclosed |
| EP-2707358-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbvie Deutschland GmbH & Co. KG (DE) | 2014-03-19 | — | — | EP | disclosed |
| US-20140045857-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045857-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045856-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045856-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-8604019-B2 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130225549-A1 | DIHYDROPTERIDINONES I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225549-A1 | DIHYDROPTERIDINONES I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-8507477-B2 | 3- and 6-quinolines with N-attached heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507477-B2 | 3- and 6-quinolines with N-attached heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN-LA ROCHE INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2013053658-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-18 | — | — | WO | disclosed |
| US-20130090328-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | Hoffmann-La Roche Inc (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2013020993-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | WO | disclosed |
| US-8343961-B2 | Substituted heterocyclic compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120316153-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-12-13 | — | — | US | disclosed |
| WO-2012152915-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-15 | — | — | WO | disclosed |
| US-20120283229-A1 | 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120270862-A1 | 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-25 | — | — | US | disclosed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20120209005-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8242264-B2 | Process for preparing 4-acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the intermediates thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2012-08-14 | — | — | US | disclosed |
| US-8242264-B2 | Process for preparing 4-acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the intermediates thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2012-08-14 | — | — | US | disclosed |
| US-8242264-B2 | Process for preparing 4-acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the intermediates thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2012-08-14 | — | — | US | disclosed |
| EP-2414361-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ArQule, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2163538-B1 | PREPARATION METHODS OF 4-ACETYL-2,3,4,5-TETRAHYDRO- BENZO[1,4]DIAZEPINE AND THEIR INTERMEDIATES | TOPHARMAN SHANGHAI CO LTD (CN) | 2012-01-25 | — | — | EP | disclosed |
| EP-2163538-B1 | PREPARATION METHODS OF 4-ACETYL-2,3,4,5-TETRAHYDRO- BENZO[1,4]DIAZEPINE AND THEIR INTERMEDIATES | TOPHARMAN SHANGHAI CO LTD (CN) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110306604-A1 | 3- AND 6-QUINOLINES WITH N-ATTACHED HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
| US-20110306604-A1 | 3- AND 6-QUINOLINES WITH N-ATTACHED HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
| US-8063038-B2 | vasopressin V2 receptor agonists for treating nocturnal enuresis, nocturia, diabetes insipidus, urinary incontinence and bleeding disorders; {1-[4-(5H,11H-Benzo[e]pyrrolo[1,2- alpha ][1,4]diazepine-10-carbonyl)-2-methylbenzylcarbamoyl]-8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl}acetic acid ethyl ester | VANTIA LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| US-8063038-B2 | vasopressin V2 receptor agonists for treating nocturnal enuresis, nocturia, diabetes insipidus, urinary incontinence and bleeding disorders; {1-[4-(5H,11H-Benzo[e]pyrrolo[1,2- alpha ][1,4]diazepine-10-carbonyl)-2-methylbenzylcarbamoyl]-8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl}acetic acid ethyl ester | VANTIA LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| US-20110021599-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-01-27 | — | — | US | disclosed |
| US-20100256358-A1 | Process for Preparing 4-Acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the Intermediates Thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2010-10-07 | — | — | US | disclosed |
| US-20100256358-A1 | Process for Preparing 4-Acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the Intermediates Thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2010-10-07 | — | — | US | disclosed |
| US-20100256358-A1 | Process for Preparing 4-Acetyl-2,3,4,5-tetrahydro-benzo[1,4]diazepine and the Intermediates Thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2010-10-07 | — | — | US | disclosed |
| WO-2010114894-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249115-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2010107605-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-09-23 | — | — | WO | disclosed |
| US-7781427-B2 | Process for preparing quinoline compounds and products obtained therefrom | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781427-B2 | Process for preparing quinoline compounds and products obtained therefrom | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100196714-A1 | PROCESS FOR PREPARING QUINOLINE COMPOUNDS AND PRODUCTS OBTAINED THEREFROM | WYETH (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100196714-A1 | PROCESS FOR PREPARING QUINOLINE COMPOUNDS AND PRODUCTS OBTAINED THEREFROM | WYETH (US) | 2010-08-05 | — | — | US | disclosed |
| US-7759338-B2 | Soluble 1,4 benzodiazepine compounds and stable salts thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759338-B2 | Soluble 1,4 benzodiazepine compounds and stable salts thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-07-20 | — | — | US | disclosed |
| CN-101270093-B | A method for synthesizing 2,3,4, 5-tetrahydro-1H-1, 4-benzodiazepine | DALIAN CHEMPHY FINE CHEMICAL CO LTD | 2010-06-16 | — | — | CN | disclosed |
| CN-101270093-B | A method for synthesizing 2,3,4, 5-tetrahydro-1H-1, 4-benzodiazepine | DALIAN CHEMPHY FINE CHEMICAL CO LTD | 2010-06-16 | — | — | CN | disclosed |
| CN-101270093-B | A method for synthesizing 2,3,4, 5-tetrahydro-1H-1, 4-benzodiazepine | DALIAN CHEMPHY FINE CHEMICAL CO LTD | 2010-06-16 | — | — | CN | disclosed |
| US-20100143322-A1 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT PATENT & LICENCE TRADING LTD., C/O THE B-NET (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100137287-A1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137287-A1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| CN-101686983-A | Aryl and heteroaryl substituted tetrahydrobenzo-1, 4-diazepine and their use for blocking the reuptake of norepinephrine, dopamine and 5-hydroxytryptamine | AMR TECHNOLOGY INC | 2010-03-31 | — | — | CN | disclosed |
| CN-101686983-A | Aryl and heteroaryl substituted tetrahydrobenzo-1, 4-diazepine and their use for blocking the reuptake of norepinephrine, dopamine and 5-hydroxytryptamine | AMR TECHNOLOGY INC | 2010-03-31 | — | — | CN | disclosed |
| US-7687620-B2 | [1,4]diazepino[6,7,1-IJ]quinoline derivatives as antipsychotic and antiobesity agents | WYETH LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687620-B2 | [1,4]diazepino[6,7,1-IJ]quinoline derivatives as antipsychotic and antiobesity agents | WYETH LLC (US) | 2010-03-30 | — | — | US | disclosed |
| EP-2163538-A1 | PREPARATION METHODS OF 4-ACETYL-2,3,4,5-TETRAHYDRO- BENZO[1,4]DIAZEPINE AND THEIR INTERMEDIATES | Topharman Shanghai Co., Ltd. (CN) | 2010-03-17 | — | — | EP | disclosed |
| EP-2163538-A1 | PREPARATION METHODS OF 4-ACETYL-2,3,4,5-TETRAHYDRO- BENZO[1,4]DIAZEPINE AND THEIR INTERMEDIATES | Topharman Shanghai Co., Ltd. (CN) | 2010-03-17 | — | — | EP | disclosed |
| WO-2010021919-A1 | 3- AND 6-QUINOLINES WITH N-ATTACHED HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-1778677-B1 | HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS | VANTIA LTD (GB) | 2010-02-03 | — | — | EP | disclosed |
| EP-2146722-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| EP-2146722-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-20090118255-A1 | Crp Lowering Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118255-A1 | Crp Lowering Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090082333-A1 | REMEDY FOR XANTHOMA | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082333-A1 | REMEDY FOR XANTHOMA | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| WO-2008141081-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141081-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080234250-A1 | Heterocyclic Condensed Compounds Useful as Antidiuretic Agents | FERRING B.V. | 2008-09-25 | — | — | US | disclosed |
| US-20080234250-A1 | Heterocyclic Condensed Compounds Useful as Antidiuretic Agents | FERRING B.V. | 2008-09-25 | — | — | US | disclosed |
| CN-101270093-A | Novel method for synthesizing 2,3,4,5-tetrahydric--1H-1,4-benzodiazepine | DALIAN CHEMPHY FINE CHEMICAL C (CN) | 2008-09-24 | — | — | CN | disclosed |
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1497293-B1 | (1,4)DIAZEPINO(6,7,1-IJ)QUINOLINE DERIVATIVES AS ANTI PSYCHOTIC AND ANTIOBESITY AGENTS | WYETH CORP (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20080113965-A1 | Compound having inhibitory activity against squalene synthase or a salt or prodrug thereof, for example, N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid; myalgia or rhabdomyolysis treatment | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-15 | — | — | US | disclosed |
| US-20080113965-A1 | Compound having inhibitory activity against squalene synthase or a salt or prodrug thereof, for example, N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid; myalgia or rhabdomyolysis treatment | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-15 | — | — | US | disclosed |
| US-20080058310-A1 | High-density lipoprotein-cholesterol level elevating agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-06 | — | — | US | disclosed |
| US-20080058310-A1 | High-density lipoprotein-cholesterol level elevating agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-06 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20080009480-A1 | CYCLOPENTA[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES | WYETH (US) | 2008-01-10 | — | — | US | disclosed |
| EP-1867639-A1 | UREA DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE OF THESE | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-7271163-B2 | Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives | WYETH (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271162-B2 | Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives | WYETH (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271164-B2 | Cyclohepta[b][1,4]diazepino[6,7,1,-hi]indoles and derivatives | WYETH (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-7176195-B2 | Fused azepine derivatives and their use as antidiuretic agents | FERRING BV (NL) | 2007-02-13 | — | — | US | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20070004707-A1 | [1,4]Diazepino[6,7,1-IJ]quinoline derivatives as antipsychotic and antiobesity agents | RAMAMOORTHY P S | 2007-01-04 | — | — | US | disclosed |
| US-20070004707-A1 | [1,4]Diazepino[6,7,1-IJ]quinoline derivatives as antipsychotic and antiobesity agents | RAMAMOORTHY P S | 2007-01-04 | — | — | US | disclosed |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISIHARA YUJI | 2006-12-14 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-7129237-B2 | [1,4]Diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | WYETH (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| EP-1640021-A1 | PREVENTIVE/REMEDY FOR URINARY DISTURBANCE | Takeda Pharmaceutical Company Limited (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
| US-7008938-B2 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | NOKIA CORPORATION (FI) | 2006-03-07 | — | — | US | disclosed |
| WO-2006018443-A1 | HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS | FERRING B.V. (NL) | 2006-02-23 | — | — | WO | disclosed |
| EP-1604653-A1 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-20050234041-A1 | Substituted 1-benzazepines and derivatives thereof | BIOPORT R&D, INC. | 2005-10-20 | — | — | US | disclosed |
| EP-1392317-A4 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-6949642-B2 | Production of tertiary amines by reductive amination | BRISTOL-MYERS SQUIBB CO. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| US-20050054635-A1 | Cyclohepta[b][1,4]diazepino[6,7,1,-hi]indoles and derivatives | WYETH (US) | 2005-03-10 | — | — | US | disclosed |
| US-6858604-B2 | Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives | WYETH (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1229913-A4 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA INC (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20050009755-A1 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| EP-1481975-A1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004098609-A1 | BENZOTRIAZEPINE DERIVATIVES AND THEIR USE AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
| US-20040229865-A1 | Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives | WYETH | 2004-11-18 | — | — | US | disclosed |
| US-6809092-B2 | 1,3,4,5-TETRAHYDRO-2H-2-BENZAZEPIN-2-YL DERIVATIVES; CYSTEINE PROTEASE INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-26 | — | — | US | disclosed |
| EP-0892797-A4 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-1097920-B1 | Intermediate for condensed benzazepine derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 2004-09-22 | — | — | EP | disclosed |
| EP-1027042-A4 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL MYERS SQUIBB CO (US) | 2004-08-18 | — | — | EP | disclosed |
| US-6777407-B2 | 7BH-CYCLOPENTA(B)(1,4)DIAZEPINO(6, 7, 1-HI)INDOLE OR A SALT, USEFUL FOR TREATMENT OF SCHIZOPHRENIA, OBSESSIVE COMPULSIVE DISORDER, DEPRESSION, ANXIETY, PANIC DISORDER, OBESITY OR EPILEPSY | WYETH | 2004-08-17 | — | — | US | disclosed |
| EP-1147095-B1 | 2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH CORP (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6770647-B2 | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-03 | — | — | US | disclosed |
| US-6759405-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-07-06 | — | — | US | disclosed |
| US-20040116457-A1 | Agents for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| US-6723711-B2 | VASCULAR CELL ADHESION MOLECULES AND FIBRONECTINS; ASTHMA, MULTIPLE SCLEROSIS, ARTHRITIS, INFLAMMATORY BOWEL DISEASE, CONTACT HYPERSENSITIVITY, CARDIAC ALLOGRAFT REJECTION AND DIABETES TREATMENT | TEXAS BIOTECHNOLOGY CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-20040063699-A1 | Gpr14 antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20040053826-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1392317-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | Antexpharma, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20040009970-A1 | [1,4]Diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | WYETH | 2004-01-15 | — | — | US | disclosed |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | NOKIA CORPORATION (FI) | 2003-08-28 | — | — | US | disclosed |
| EP-1331010-A1 | PREVENTIVES AND REMEDIES FOR CENTRAL NERVOUS SYSTEM DISEASES | Takeda Chemical Industries, Ltd. (JP) | 2003-07-30 | — | — | EP | disclosed |
| US-20030130257-A1 | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-10 | — | — | US | disclosed |
| EP-1310490-A1 | GPR14 ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-0709386-B1 | FUSED BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMA CO LTD (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6544984-B1 | Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. | AMERICAN CYANAMID COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-6514965-B1 | For treating bacterial infections | ANTEX PHARMA INC. | 2003-02-04 | — | — | US | disclosed |
| US-6503900-B2 | For treatment or prevention of disorders such as obsessive-compulsive disorder, depression, anxiety, schizophrenia | WYETH | 2003-01-07 | — | — | US | disclosed |
| WO-2002100327-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| US-20020169313-A1 | Production of tertiary amines by reductive amination | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-14 | — | — | US | disclosed |
| EP-1254898-A1 | BENZENE-FUSED HETEROCYCLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | disclosed |
| US-6455523-B1 | ADMINISTERING 1,4-BENZODIAZEPINE DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20020128261-A1 | Cyclohepta [b] [1,4] diazepino [6,7, 1-hi] indoles and derivatives | AMERICAN HOME PRODUCTS CORPORATION | 2002-09-12 | — | — | US | disclosed |
| US-20020119966-A1 | Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-08-29 | — | — | US | disclosed |
| EP-1229913-A1 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | Antexpharma, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| US-20020086860-A1 | [1,4]Diazepino [6,7,1-jk] carbazoles and derivatives | AMERICAN HOME PRODUCTS CORPORATION | 2002-07-04 | — | — | US | disclosed |
| WO-2002036596-A2 | CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES | WYETH (US) | 2002-05-10 | — | — | WO | disclosed |
| US-20020019389-A1 | Urea derivative useful as an anti-cancer agent and process for preparing same | CHACONNE NSI CO., LTD. (KR) | 2002-02-14 | — | — | US | disclosed |
| US-6319916-B1 | CHOLINESTERASE INHIBITOR FOR SENILE DEMENTIA AND ALZHEIMER'S TREATMENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-11-20 | — | — | US | disclosed |
| WO-2001081322-A1 | NON-IMIDAZOLE BENZODIAZEPINE INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-1140192-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140194-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINED TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140177-A2 | USE OF AN INTEGRIN ANTAGONIST AND RADIATION IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140193-A2 | USE OF AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140183-A1 | USE OF A MATRIX METALLOPROTEINASE INHIBITOR AND AN INTEGRIN ANTAGONIST IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140179-A2 | USE OF A CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| WO-2001035964-A1 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| EP-1097920-A1 | Intermediate for condensed benzazepine derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2001-05-09 | — | — | EP | disclosed |
| US-6225465-B1 | REACTING BENZOAZEPINE OR BENZODIAZEPINE DERIVATIVE WITH PROTECTED AMINE IN PRESENCE OF PALLADIUM CATALYST IN PRESENCE OF CARBON MONOXIDE, REMOVING PROTECTING GROUPS | SMITHKLINE BEECHAM PLC (GB) | 2001-05-01 | — | — | US | disclosed |
| EP-1051407-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000063186-A1 | PROCESS AND INTERMEDIATES FOR PREPARING BENZODIAZEPINES | SMITHKLINE BEECHAM PLC (GB) | 2000-10-26 | — | — | WO | disclosed |
| EP-1027042-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-08-16 | — | — | EP | disclosed |
| EP-1019383-A2 | PROCESS FOR THE AMINOCARBONYLATION OF BENZAZEPINES AND BENZODIAZEPINES | SMITHKLINE BEECHAM PLC (GB) | 2000-07-19 | — | — | EP | disclosed |
| WO-2000038730-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038719-A1 | USE OF A MATRIX METALLOPROTEINASE INHIBITOR AND AN INTEGRIN ANTAGONIST IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038665-A2 | USE OF AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038715-A2 | USE OF AN INTEGRIN ANTAGONIST AND RADIATION IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000037107-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINATION TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-06-29 | — | — | WO | disclosed |
| US-6071903-A | ENZYME INHIBITORS OF MATRIX METALLOPROTEINASES (MMPS); ANTITUMOR,-CARCINOGENIC AND -ARTHRITIC AGENTS; OSTEOARTHRITIS; RHEUMATOID DISEASES; DEGENERATIVE CARTILAGE LOSS; LONG-ACTING, ORALLY BIOAVAILABLE NONPEPTIDE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-06-06 | — | — | US | disclosed |
| US-6011029-A | BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
| WO-1999037625-A1 | 2,3,4,5-TETRAHYDRO-1H-[1,4]-BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999018951-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-04-22 | — | — | WO | disclosed |
| EP-0892797-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| US-5856564-A | CHEMICAL INTERMEDIATE FOR VASOPRESSIN ANTAGONIST | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1999-01-05 | — | — | US | disclosed |
| US-5723606-A | Condensed benzazepine derivative and pharmaceutical composition thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1998-03-03 | — | — | US | disclosed |
| WO-1997030992-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
| WO-1997024336-A2 | PROCESS FOR THE AMINOCARBONYLATION OF BENZAZEPINES AND BENZODIAZEPINES | SMITHKLINE BEECHAM PLC (GB) | 1997-07-10 | — | — | WO | disclosed |
| EP-0709386-A1 | FUSED BENZAZEPINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-05-01 | — | — | EP | disclosed |
| EP-0450097-B1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 1996-04-24 | — | — | EP | disclosed |
| EP-0567090-A2 | Benzoxazepine derivatives as cholinesterase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-27 | — | — | EP | disclosed |
| US-4406835-A | Tranquillo-sedative benzodiazepine derivatives | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1983-09-27 | — | — | US | disclosed |
| US-4045433-A | SEDATIVES | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1977-08-30 | — | — | US | disclosed |
| US-4044003-A | Process for preparing 1,4-benzodiazepines | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-08-23 | — | — | US | disclosed |
| US-4021421-A | ENZYME INDUCING ACTIVITY | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1977-05-03 | — | — | US | disclosed |
| US-4021421-A | ENZYME INDUCING ACTIVITY | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086860-A1 | [1,4]Diazepino [6,7,1-jk] carbazoles and derivatives | GRIK1, GRIK3, GRIK4 | CD44 3726/4885PNMT 1293/4885MAOB 352/4885 |
| US-10870635-B2 | Compounds and their use as BACE1 inhibitors | BACE1, BACE2, APP | CD44 4712/4885PNMT 1365/4885MAOB 442/4885 |
| US-10683256-B2 | Process for preparing substituted biphenyls | PIK3CA, PIK3CB, PIK3CG | CD44 4145/4885PNMT 732/4885MAOB 1285/4885 |
| US-20070004707-A1 | [1,4]Diazepino[6,7,1-IJ]quinoline derivatives as antipsychotic and antiobesity agents | HTR2C, HTR1A, HTR1D | CD44 4883/4885PNMT 445/4885MAOB 530/4885 |
| US-20110021599-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | AR, BPHL, PTGS2 | CD44 2410/4885PNMT 4151/4885MAOB 1013/4885 |
| US-11535607-B2 | Isoindolines as HDAC inhibitors | HDAC1, HDAC2, HDAC3 | CD44 3820/4885PNMT 2919/4885MAOB 822/4885 |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | CD44 1818/4885PNMT 65/4885MAOB 53/4885 |
| US-20120209005-A1 | FUSED HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | MPL, TEK, THPO | CD44 1960/4885PNMT 4809/4885MAOB 1276/4885 |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | CD44 3060/4885PNMT 96/4885MAOB 248/4885 |
| US-20160346186-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | AR, BPHL, PTGS2 | CD44 2410/4885PNMT 4151/4885MAOB 1013/4885 |
| US-20180071408-A1 | CHOLECYSTOKININ 2 RECEPTOR TARGETED NIR IMAGING AND USE THEREOF | CCKAR, CCKBR, GRPR | CD44 852/4885PNMT 2529/4885MAOB 3550/4885 |
| US-20120283229-A1 | 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES | ROCK1, ROCK2, GABRR1 | CD44 3593/4885PNMT 1381/4885MAOB 723/4885 |
| US-10786580-B2 | Cholecystokinin 2 receptor targeted NIR imaging and use thereof | CCKAR, CCKBR, GRPR | CD44 852/4885PNMT 2529/4885MAOB 3550/4885 |
| US-20030130257-A1 | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAMTS1, ADAM17, MMP1 | CD44 294/4885PNMT 4802/4885MAOB 633/4885 |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | CD44 3911/4885PNMT 2949/4885MAOB 870/4885 |
| US-20090082333-A1 | REMEDY FOR XANTHOMA | FDFT1, LSS, SQLE | CD44 4300/4885PNMT 3501/4885MAOB 1030/4885 |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | LIPA, ALG1, CEL | CD44 645/4885PNMT 1202/4885MAOB 791/4885 |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | CD44 4772/4885PNMT 174/4885MAOB 207/4885 |
| US-20100249115-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CYP11B2, GABBR1, CNR1 | CD44 3293/4885PNMT 291/4885MAOB 248/4885 |
| US-20020019389-A1 | Urea derivative useful as an anti-cancer agent and process for preparing same | UTS2R, SLC14A1, URB2 | CD44 1209/4885PNMT 3821/4885MAOB 1452/4885 |
| US-20080132483-A1 | Agent for preventing or treating organ functional disorders and organ dysfunction | FDFT1, SQOR, DHPS | CD44 3804/4885PNMT 1276/4885MAOB 1718/4885 |
| US-20210101891-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | EP300, HDAC11, HDAC1 | CD44 4040/4885PNMT 869/4885MAOB 1553/4885 |
| US-20080234250-A1 | Heterocyclic Condensed Compounds Useful as Antidiuretic Agents | AVPR2, AVPR1A, AVPR1B | CD44 4249/4885PNMT 2232/4885MAOB 2008/4885 |
| US-20140045857-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | PDE12, PDE2A, PDE3A | CD44 4845/4885PNMT 77/4885MAOB 94/4885 |
| US-20130225549-A1 | DIHYDROPTERIDINONES I | BACE1, APP, BACE2 | CD44 2920/4885PNMT 3048/4885MAOB 2074/4885 |
| US-20080161294-A1 | Urea derivative, medicinal composition containing the same, and medicinal use of these | AVPR2, UTS2R, GPR119 | CD44 4322/4885PNMT 1501/4885MAOB 1045/4885 |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | BACE1, BACE2, APP | CD44 4688/4885PNMT 1458/4885MAOB 365/4885 |
| US-20140080816-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | CD44 4876/4885PNMT 156/4885MAOB 194/4885 |
| US-20200148610-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | LIPA, ALG1, CEL | CD44 645/4885PNMT 1202/4885MAOB 791/4885 |
| US-20040229865-A1 | Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives | HTR1A, HCRTR2, HTR3B | CD44 3275/4885PNMT 935/4885MAOB 19/4885 |
| US-20200283439-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | CD44 4876/4885PNMT 156/4885MAOB 194/4885 |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | BDKRB1, CALCRL, BDKRB2 | CD44 4664/4885PNMT 2270/4885MAOB 366/4885 |
| US-20250154114-A1 | MATERIAL FOR METAL PATTERNING, HETEROCYCLIC COMPOUND, THIN FILM FOR METAL PATTERNING, ORGANIC ELECTROLUMINESCENT DEVICE, ELECTRONIC DEVICE, AND METHOD FOR FORMING METAL PATTERN | NES, L1CAM, MNS1 | CD44 1957/4885PNMT 278/4885MAOB 99/4885 |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | CFTR, H1-10, RECQL | CD44 2542/4885PNMT 3559/4885MAOB 1957/4885 |
| US-20190210954-A1 | Process for Preparing Substituted Biphenyls | PIK3CA, PIK3CB, PIK3CG | CD44 4145/4885PNMT 732/4885MAOB 1285/4885 |
| US-20020128261-A1 | Cyclohepta [b] [1,4] diazepino [6,7, 1-hi] indoles and derivatives | TPH1, HTR1A, FAAH | CD44 2508/4885PNMT 669/4885MAOB 39/4885 |
| US-20120316153-A1 | BENZAZEPINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A11, SLC6A1, KCNB2 | CD44 4285/4885PNMT 240/4885MAOB 174/4885 |
| US-20020169313-A1 | Production of tertiary amines by reductive amination | FNTB, ACAT2, SOAT2 | CD44 3901/4885PNMT 86/4885MAOB 85/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | CD44 4662/4885PNMT 153/4885MAOB 259/4885 |
| US-10836688-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | LIPA, ALG1, CEL | CD44 645/4885PNMT 1202/4885MAOB 791/4885 |
| US-20100137287-A1 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ADRA1B, ADRB1, ADRA1D | CD44 4489/4885PNMT 134/4885MAOB 31/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | CD44 3060/4885PNMT 96/4885MAOB 248/4885 |
| US-20080058310-A1 | High-density lipoprotein-cholesterol level elevating agent | SREBF1, SREBF2, HDLBP | CD44 4663/4885PNMT 3515/4885MAOB 2993/4885 |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | ATP5F1A, ATP5MF, MT-ATP6 | CD44 2615/4885PNMT 3664/4885MAOB 2528/4885 |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | CD44 4760/4885PNMT 2276/4885MAOB 333/4885 |
| US-20120270862-A1 | 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES | ROCK1, ROCK2, GABRR1 | CD44 3747/4885PNMT 1356/4885MAOB 839/4885 |
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | CD44 1294/4885PNMT 677/4885MAOB 1973/4885 |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | CD44 4784/4885PNMT 159/4885MAOB 233/4885 |
| US-20020119966-A1 | Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives | HTR1A, HCRTR2, HTR3B | CD44 3275/4885PNMT 935/4885MAOB 19/4885 |
| US-20140045856-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | PDE12, PDE2A, PDE3A | CD44 4845/4885PNMT 77/4885MAOB 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.